

WEST

☐ Generate Collection

L1: Entry 3 of 9

File: DWPI

Jan 21, 1997

DERWENT-ACC-NO: 1997-140823
DERWENT-WEEK: 199713
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Anti-stress compsn. for food or drink - contains imidazole cpd. e.g. anserine and/or pi-methyl-histidine

PATENT-ASSIGNEE:

ASSIGNEE

CODE

SUNTORY LTD

SUNR

PRIORITY-DATA: 1995JP-0168860 (July 4, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 09020660 A	January 21, 1997		008	A61K031/415

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP09020660A	July 4, 1995	1995JP-0168860	

INT-CL (IPC): A23 L 1/305; A61 K 31/415; A61 K 38/00

ABSTRACTED-PUB-NO: JP09020660A
BASIC-ABSTRACT:

Antistress compsn. contains at least one imidazole cpd. selected from anserine, valenine, pi-methylhistidine and tau-methylhistidine.

Also claimed are a new food and drink prepd. by adding at least one imidazole cpd. selected from anserine, valenine, pi-methylhistidine and tau-methylhistidine to a food or drink contg. no anserine, valenine, pi-methylhistidine or tau-methylhistidine, and prepn. of the food or drink in which at least one imidazole cpd. is added to a food or drink.

ADVANTAGE - The compsn. prevents physical and mental stress and promotes recovery from stress.

In an example, 100 mg/kg L-anserine was dosed subcutaneously to a 7 weeks old female mouse once a day for 5 days. Restriction stress was loaded for 20 hrs. and then the stress load was evaluated by using the blood insulin concn. after 2 days as the index. A control using physiological saline water gave a value of 34.7% of normal level. The dose of L-anserine gave 72.5% of normal level. Insulin secretion lowered by involuntary mental stress was increased to show an antistress effect of L-anserine.

CHOSEN-DRAWING: Dwg.0/4

TITLE-TERMS: ANTI STRESS COMPOSITION FOOD DRINK CONTAIN IMIDAZOLE COMPOUND ANSERINE PI METHYL HISTIDINE

DERWENT-CLASS: B03 D13 E13

CPI-CODES: B07-D09; B14-J01B4; D03-H01T2; E07-D09;

CHEMICAL-CODES:

WEST

Generate Collection

Print

L1: Entry 6 of 9

File: DWPI

Apr 11, 1995

DERWENT-ACC-NO: 1995-175329

DERWENT-WEEK: 199523

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Iron absorption promoting agent for treating anaemia, headaches, dyskinesia etc.
- contains at least one of calcinone, anceline, valenine and pi-methyl:histidine, for
addn. to food or drink

PATENT-ASSIGNEE:

ASSIGNEE

SUNTORY LTD

CODE

SUNR

PRIORITY-DATA: 1993JP-0106981 (May 7, 1993)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

JP 07097323 A

April 11, 1995

009

A61K031/415

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

JP07097323A

May 9, 1994

1994JP-0095176

INT-CL (IPC): A23 L 1/305; A61 K 31/415; A61 K 38/00

ABSTRACTED-PUB-NO: JP07097323A

BASIC-ABSTRACT:

Iron absorption promoting agent contains at least one imidazole cpd. selected from calcinone (beta-alanyl-L-histidine), anceline (beta-alanyl- pi-methyl-L-histidine), valenine (beta-alanyl- tau-methyl-L- histidine) and pi-methylhistidine.

Also claimed are (i) an iron absorption promoting agent contg. anceline; (ii) food and drink having iron absorption promoting action comprising at least one imidazole cpd. as above, or an extract contg. them as the main ingredient, added to food and drink contg. no calcinone, anceline, valenine or pi-methyl histidine; (iii) food and drink having iron absorption promoting action comprising anceline or extract contg. anceline as the main ingredient added to food and drink contg. no anceline; and (iv) prepn. of these food and drink.

Pref. food and drink contain 50mg to 5g/day of anceline.

ADVANTAGE - Agent has low toxicity and high safety, and may be used for anaemia, headache, 'ringing in the ears', shortness of breath, dyskinesia, and iron deficiency after blood donation, operation and childbirth.

In an example, to 30mM sodium phosphate buffer (pH 7.40), apotransferrin was dissolved to adjust 123 micro-M. To the solution (900 micro-litre), calcinone (5 mM), calcinone (5mM) + copper(II) (2.5 micro-M), calcinone (5mM) + copper(II) (25 micro-M) or calcinone (5mM) + copper(II) (250 micro-M) (900 micro-litre, respectively) was added and incubated at 30 deg.C for 5 minutes, then stirred at 30 deg.C. 1mM, aq. iron (II) sulphate (200 micro-litre) was added, respectively, to start the reaction, and 460 nm absorbance was detected for 2 minutes with the synthesis of iron-transferrin complex. Ferro-oxidase activity was 0.604, 1.245, 1.216 and 0.547 micro-M/sec., and the activity of the control (H2O) was 0.780 micro-M/sec.